WHO launches bold new plan to close the childhood cancer survival gap

The World Health Organization (WHO) and its partners in the Global Platform for Access to Childhood Cancer Medicines have launched a sweeping new strategy aimed at fixing the broken market for childhood cancer medicines in low- and middle-income countries (LMICs). Released during Childhood Cancer Awareness Month, the Market Shaping Strategy 2026–2030 lays out ten interlinked interventions — from broadening the quality-assured supplier base and pooling procurement demand, to deploying volume guarantees and pursuing voluntary licensing for newer therapies.

The strategy comes alongside a landmark move: WHO issued its first-ever Expression of Interest inviting manufacturers to submit 12 priority childhood cancer medicines for WHO prequalification — six needing child-friendly formulations and six facing critical supply gaps. Together, these steps aim to diversify suppliers, reduce regulatory barriers, and make life-saving treatments more reliably available to children everywhere.

By the Numbers

• ~400,000 children develop cancer each year globally
• <30% survival rate in LMICs vs. >80% in high-income countries
• Only ~45% of essential childhood cancer medicines were available across 51 hospitals surveyed in 12 countries
• Nearly half of those medicines were out of stock for at least one month in the prior year
• ~500,000 children in 90 countries have already benefited from the Global Initiative for Childhood Cancer since 2018

Why it matters: Where a child is born should not determine whether they survive cancer. This strategy creates a concrete, multi-stakeholder roadmap to stabilize medicine supply chains and make treatment accessible — and its market-shaping lessons could extend to other noncommunicable diseases as well.